Dr. Liu obtained his BS in Chemistry and Chemical Engineering from Tsinghua University, MS in Polymer Materials from Chengdu University of Science and Technology (now Sichuan University), and Ph.D in Biomaterials from Twente University in the Netherlands.  He has done postdoctoral research in tissue engineering and biomaterials at Rice University and Temple University in the United States. He used to be the R&D director of biomaterials and tissue engineering in Celgene, an international biopharmaceutical company. He has rich experience in international company product development, enterprise management, GMP production of medical device products and FDA product approval.  In 2007, he founded 3D Biotek. In the same year, he was recognized as a high-tech biotechnology enterprise after being reviewed by the New Jersey state government and settled in the Commercialization Center For Innovation Technologies, a high-tech enterprise park funded by the New Jersey state government.  In 2009, he won the "2009 Most Notable High-Tech Startup Award" by the New Jersey Technology Association. As the project leader, he undertook the Small Business Innovation Fund Project (SBIR) of the National Institutes of Health and the famous New Jersey Edison Innovation Fund project, and engaged in the research and development of new tissue engineering products and absorbable vascular stents.

Dr. Qing Liu is a standing member of the Vascular Device Branch of the China Medical Device Industry Association, the vice chairman of the Beijing Huayan Vascular Disease Diagnosis and Treatment Industry Technology Innovation Strategic Alliance, an expert member of the Research and Transformation Committee of the Endovascular Vascular Association of the Chinese Medical Doctor Association, and the Chinese Society of Biomaterials. Member of the Regenerative Medicine Materials Branch, and director of the Beijing Biomedical Engineering Society.

Dr. Zhao obtained his BS from Sichuan University, MS and Ph.D. from Case Western Reserve University.  Before joining AMET, he had worked as a research scientist at well-known companies such as Medtronic and Abbott in the United States.  For over 30 years, he has been engaged in the research and development of various implantable medical devices including pacemaker leads, cardiovascular stents, artificial blood vessels, human soft tissue repair materials, artificial hearts (LVAD), and biomaterials.  Many R&D products under his leadership and participation have come to commercialization in the international markets. 

Dr. Nikanorov, an interventional radiologist, a physician-scientist, is renowned for his medical device innovations, collaborative academic research and medical education.  As a TCT Fellow, working with international colleagues he managed the global development and growth of new scientific cardiovascular congresses for more than 10 years. He worked as Medical Director at Abbott Laboratories and Sr. Jude Medical on the development and commercialization of a variety of cardiovascular medical devices. Dr. Nikanorov brings to AMET rich experience in medical science and clinical research on cardiovascular products.